SG11201912864SA - Multi-specific antibodies and methods of making and using thereof - Google Patents

Multi-specific antibodies and methods of making and using thereof

Info

Publication number
SG11201912864SA
SG11201912864SA SG11201912864SA SG11201912864SA SG11201912864SA SG 11201912864S A SG11201912864S A SG 11201912864SA SG 11201912864S A SG11201912864S A SG 11201912864SA SG 11201912864S A SG11201912864S A SG 11201912864SA SG 11201912864S A SG11201912864S A SG 11201912864SA
Authority
SG
Singapore
Prior art keywords
making
methods
specific antibodies
antibodies
specific
Prior art date
Application number
SG11201912864SA
Other languages
English (en)
Inventor
Yi Zhu
Ole Olsen
Dong Xia
David Jellyman
Katrina Bykova
Anne-Marie Rousseau
Bill Brady
Blair Renshaw
Brian Kovacevich
Yu Liang
Zeren Gao
Original Assignee
Systimmune Inc
Sichuan Baili Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Systimmune Inc, Sichuan Baili Pharmaceutical Co Ltd filed Critical Systimmune Inc
Publication of SG11201912864SA publication Critical patent/SG11201912864SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201912864SA 2017-06-25 2018-06-22 Multi-specific antibodies and methods of making and using thereof SG11201912864SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762524557P 2017-06-25 2017-06-25
PCT/US2018/039156 WO2019005639A2 (en) 2017-06-25 2018-06-22 MULTISPECIFIC ANTIBODIES AND METHODS OF PREPARATION AND USE THEREOF

Publications (1)

Publication Number Publication Date
SG11201912864SA true SG11201912864SA (en) 2020-01-30

Family

ID=64742644

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201912864SA SG11201912864SA (en) 2017-06-25 2018-06-22 Multi-specific antibodies and methods of making and using thereof

Country Status (10)

Country Link
US (1) US11787863B2 (cg-RX-API-DMAC7.html)
EP (1) EP3645049A4 (cg-RX-API-DMAC7.html)
JP (1) JP7399852B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250024104A (cg-RX-API-DMAC7.html)
CN (4) CN116199785A (cg-RX-API-DMAC7.html)
AU (2) AU2018295118B2 (cg-RX-API-DMAC7.html)
CA (1) CA3068045A1 (cg-RX-API-DMAC7.html)
IL (2) IL313468A (cg-RX-API-DMAC7.html)
SG (1) SG11201912864SA (cg-RX-API-DMAC7.html)
WO (1) WO2019005639A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260008861A9 (en) * 2017-06-25 2026-01-08 Systimmune, Inc. Anti-4-1bb antibodies and methods of making and using thereof
SG11201912865VA (en) * 2017-06-25 2020-01-30 Systimmune Inc Multi-specific antibodies and methods of making and using thereof
JP7383605B2 (ja) * 2017-06-25 2023-11-20 システィミューン, インク. 抗pd-l1抗体とその作製及び使用方法
TW201904588A (zh) * 2017-06-25 2019-02-01 美商西雅圖免疫公司 引導及導航控制蛋白質之製造及使用方法
EP3773621A4 (en) * 2018-03-27 2022-03-23 Systimmune, Inc. GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHODS FOR THEIR MANUFACTURE AND USE
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
AU2020279224B2 (en) 2019-05-21 2024-12-05 Novartis Ag Trispecific binding molecules against BCMA and uses thereof
CN118580364A (zh) * 2019-11-06 2024-09-03 西雅图免疫公司 制导和导航控制蛋白及其制备和使用方法
EP3988568A1 (en) * 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
CN118974091A (zh) * 2022-04-11 2024-11-15 阿斯利康(瑞典)有限公司 T细胞结合蛋白
CA3262028A1 (en) * 2022-07-15 2025-06-13 Abl Bio Inc. Anti-ROR1 antibodies, bispecific antibodies containing it, and their uses
CN120813602A (zh) * 2022-12-20 2025-10-17 英克特诺治疗公司 用于治疗癌症的组合疗法
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies
CN116143934B (zh) * 2023-03-21 2023-07-25 诺赛联合(北京)生物医学科技有限公司 一种干细胞外泌体提取试剂盒及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1392359T4 (da) 2001-05-11 2013-06-10 Ludwig Inst For Cancer Res Ltd Specifikke bindingsproteiner og deres anvendelser.
CA2832136C (en) * 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
WO2007002223A2 (en) * 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
US8679502B2 (en) 2007-11-13 2014-03-25 Evec Inc. Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising same
US9365644B2 (en) * 2008-04-23 2016-06-14 Epitomics, Inc. Anti-TNFα antibody
BRPI1014089A2 (pt) 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
SG176219A1 (en) * 2009-05-27 2011-12-29 Hoffmann La Roche Tri- or tetraspecific antibodies
GB201020995D0 (en) * 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
CN103906533A (zh) * 2011-11-07 2014-07-02 米迪缪尼有限公司 多特异性和多价结合蛋白及其用途
PL3489261T3 (pl) * 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
US9732150B2 (en) * 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
HK1218549A1 (zh) 2013-06-26 2017-02-24 Numab Therapeutics AG 新型抗体框架
JP6693872B2 (ja) * 2013-07-25 2020-05-13 シトムクス セラピューティクス,インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
WO2015058861A1 (en) 2013-10-25 2015-04-30 Numab Ag Bispecific constructs and their use in the treatment of various diseases
CA3265373A1 (en) * 2014-02-20 2025-10-30 H. Lundbeck A/S Anti-acth antibodies and use thereof
UA117289C2 (uk) * 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
US10428155B2 (en) * 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
EP3253790A4 (en) * 2015-02-06 2018-07-25 University of Maryland, Baltimore Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection
CN104829733B (zh) * 2015-05-25 2018-06-05 广州百暨基因科技有限公司 抗原结合单元稳定的嵌合抗原受体及制备方法与应用
JP6932700B2 (ja) * 2015-09-15 2021-09-08 アムジエン・インコーポレーテツド 4価の二重特異性抗原結合タンパク質及び4価の四重特異性抗原結合タンパク質、ならびにそれらの使用
TW201904588A (zh) * 2017-06-25 2019-02-01 美商西雅圖免疫公司 引導及導航控制蛋白質之製造及使用方法
SG11201912865VA (en) 2017-06-25 2020-01-30 Systimmune Inc Multi-specific antibodies and methods of making and using thereof
EP3773621A4 (en) * 2018-03-27 2022-03-23 Systimmune, Inc. GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHODS FOR THEIR MANUFACTURE AND USE

Also Published As

Publication number Publication date
AU2018295118A1 (en) 2020-02-06
IL271257B2 (en) 2024-11-01
US20220002406A1 (en) 2022-01-06
KR20200092301A (ko) 2020-08-03
CN116948035A (zh) 2023-10-27
IL313468A (en) 2024-08-01
CN116041530A (zh) 2023-05-02
EP3645049A2 (en) 2020-05-06
EP3645049A4 (en) 2021-06-30
KR20250024104A (ko) 2025-02-18
RU2020102662A (ru) 2021-07-27
WO2019005639A2 (en) 2019-01-03
AU2018295118B2 (en) 2025-04-17
KR102763369B1 (ko) 2025-02-05
WO2019005639A3 (en) 2019-02-07
JP2020530777A (ja) 2020-10-29
US11787863B2 (en) 2023-10-17
IL271257B1 (en) 2024-07-01
JP7399852B2 (ja) 2023-12-18
CN110831973A (zh) 2020-02-21
CN110831973B (zh) 2023-08-15
NZ760913A (en) 2024-10-25
AU2025204860A1 (en) 2025-07-17
CA3068045A1 (en) 2019-01-03
CN116199785A (zh) 2023-06-02
IL271257A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
SG11201912865VA (en) Multi-specific antibodies and methods of making and using thereof
ZA201906730B (en) Anti-trem2 antibodies and methods of use thereof
IL275070A (en) FCRN antibodies and methods of using them
LT3618863T (lt) Anti-tigit antikūnai ir jų panaudojimo būdai
IL259495A (en) Antibodies and methods for using them
IL256086A (en) Anti-her2 antibodies and methods of use
IL254887A0 (en) Anti-sortilin antibodies and methods of using them
IL252837B (en) fcrn antibodies and methods of using them
IL259681A (en) New antibodies against claudin and methods of using them
SG11201803567XA (en) Anti-siglec-9 antibodies and methods of use thereof
SG10201912150TA (en) Anti-trem2 antibodies and methods of use thereof
IL270793A (en) Anti-HTRA1 antibodies and methods of using them
IL274221A (en) Antibodies to ANTI-APOC3 and methods of use
SG11202003237QA (en) Bispecific antibodies and methods of making and using thereof
ZA202002144B (en) Antibodies and methods of use
SMT202300278T1 (it) Anticorpi monoclonali anti cimici da letto, metodi di produzione e usi
IL275493A (en) Antibodies to centrin-1, methods for their preparation and use
AU2015901092A0 (en) PAT-SM3 related antibodies and methods of making and using same
AU2014901301A0 (en) PAT-SM3 related antibodies and methods of making and using same